HTR1B and migraine disorder: However, they also exert a central effect through activation of 5-HT1B, 5-HT1D and 5-HT1F receptors on trigeminal nerve terminals, inhibiting in turn the release of vasoactive peptides preventing vasodilatation in migraine [16].